Pathstone Holdings’s Oragenics OGEN Stock Holding History

Pathstone Holdings’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,001	Closed	-$30.8K	–	2399
2026 Q1	$30.8K	Buy	+55,001	New	+$43.5K	﹤0.01%	2199

Other funds holding OGEN

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

25 LLC St. Louis, Missouri $365M AUM 18.53% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SJIM

St. Johns Investment Management Jacksonville, Florida $264M AUM 29.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Pathstone Holdings's OGEN Position: Q2 2026 in Review

Pathstone Holdings sold out of Oragenics (OGEN) in Q2 2026, closing a stake of 55,001 shares — an estimated $30.8K sold.

Pathstone Holdings first reported a position in OGEN in Q1 2026 and held it in 1 quarter. The position peaked at $30.8K in Q1 2026. 17 funds tracked by Wall St. Rank hold OGEN as of Q2 2026.

Pathstone Holdings reported no remaining Oragenics position as of Q2 2026 after selling out during the quarter.
Pathstone Holdings sold 55,001 Oragenics shares in Q2 2026, an estimated $30.8K.
Pathstone Holdings first reported a position in Oragenics in Q1 2026 and held it in 1 quarter.
Pathstone Holdings's Oragenics position peaked at $30.8K in Q1 2026.
17 funds tracked by Wall St. Rank held Oragenics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.